The phase 3 PANOVA-3 trial, designed to evaluate concomitant treatment with tumor treating fields and chemotherapy, met its ...

Zenocutuzumab received accelerated approval from the FDA for the agent to treat non-small cell lung cancer (NSCLC) or ...

The FDA has granted fast track designation to LBS-007 for the treatment of patients with acute myeloid leukemia.

According to the American Lung Association, biomarker testing gaps and low screening rates continue to hinder lung cancer ...

Following a phase 1b trial, the potent and selective dual inhibitor of IRAK1 and IRAK4 received fast track designation for the treatment of patients with lower-risk myelodysplastic syndrome.

The FDA approved a companion diagnostic to identify patients with biliary tract cancer eligible for treatment with ...

Oncology nurses “play a pivotal role in guiding patients” through the genetic testing process, an expert explained.

The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...

The FDA granted an accelerated approval to zanidatamab-hrii for previously treated, unresectable or metastatic HER2-positve ...

The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone ...

Most patients with triple-negative breast cancer experienced a protocol-defined immune response with an investigational vaccine, phase 1 data showed. More than 70% of patients with triple-negative ...